Amgen (AMGN) Cash from Investing Activities (2009 - 2026)

Amgen has reported Cash from Investing Activities for 18 years, with the latest figure at -$569.0 million in Q2 2026.

• On a quarterly basis, Cash from Investing Activities fell 46.27% year-over-year to -$569.0 million in Q2 2026; TTM through Jun 2026 was -$2.4 billion, a 65.19% decrease from a year earlier, with the FY2025 full-year figure at -$1.9 billion, down 85.76% from the prior year.
• Cash from Investing Activities was -$569.0 million for Q2 2026 at Amgen, up from -$716.0 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $1.4 billion in Q1 2023, with the low at -$27.1 billion in Q4 2023.
• Average Cash from Investing Activities over 5 years is -$2.0 billion, with a median of -$395.5 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities plunged 1410.0% in 2022, then jumped 1323.42% in 2023.
• Over 5 years, Cash from Investing Activities stood at -$3.5 billion in 2022, then plunged by 679.99% to -$27.1 billion in 2023, then surged by 98.52% to -$402.0 million in 2024, then tumbled by 72.39% to -$693.0 million in 2025, then advanced by 17.89% to -$569.0 million in 2026.
• The last three Cash from Investing Activities figures came in at -$569.0 million (Q2 2026), -$716.0 million (Q1 2026), and -$693.0 million (Q4 2025), per Business Quant data.